Poseida Therapeutics, Inc. (2RZ.F)

2.5980 -0.0480 (-1.81%) At close: 03:29PM CEST

Poseida Therapeutics, Inc.

9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100
https://poseida.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 330

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Mark J. Gergen J.D.	Executive Chairman of the Board	896.4k	N/A	1963
Dr. Kristin Yarema Ph.D.	President, CEO & Director	663.57k	N/A	1971
Ms. Johanna M. Mylet CPA	Chief Financial Officer	N/A	N/A	1988
Mr. Loren Wagner	Chief Operations Officer	N/A	N/A	N/A
Ms. Kristin Martin	Chief People & Administration Officer	N/A	N/A	N/A
Mr. Alexander Chapman	Senior VP of Investor Relations & Corporate Communications	N/A	N/A	N/A
Mr. Harry J. Leonhardt Esq., J.D.	General Counsel, Chief Compliance Officer & Corporate Secretary	587.38k	N/A	1957
Dr. Devon J. Shedlock Ph.D.	Chief Scientific Officer of Cell Therapy	N/A	N/A	N/A
Ms. Lisa Portale	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Jeffrey W. Winkelman J.D., Ph.D.	Senior VP & Chief Patent Counsel	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

Corporate governance

Poseida Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.